FAK-IN-4 (Compound 7d) exhibits anticancer activities by inducing cell apoptosis and is a potential inhibitor of FAK [1].

FAK-IN-4 (Compound 7d), at concentrations ranging from 0-200 µM over 72 hours, exhibits significant antiproliferative effects on triple-negative breast cancer (TNBC) cells [1]. At lower concentrations of 0-20 µM for 24 hours, it effectively inhibits cell invasion and migration in MDA-MB-231 cells [1]. Additionally, within the same concentration range but over a longer period of 72 hours, FAK-IN-4 induces a dose-dependent dephosphorylation of FAK at Y925 and promotes apoptosis in MDA-MB-231 cells [1]. It also disrupts the formation of focal adhesions (FAs) and stress fibers (SFs) in these cells [1]. Through cell proliferation assays involving various cell lines (MDA-MB-231, MDA-MB-157, MDA-MB-453, and MCF10A) and concentrations up to 200 µM for 72 hours, the growth of TNBC cells was inhibited with IC50 values ranging from 8.37 to 40.63 µM [1]. Cell invasion assays at concentrations of 5, 10, and 20 µM over 24 hours significantly reduced the invasion of MDA-MB-231 cells in a dose-dependent manner [1]. Western blot analysis confirmed the dose-dependent dephosphorylation of FAK at Y925 [1]. Apoptosis analysis, using the same cell line and concentration range over 72 hours, demonstrated an increase in apoptotic cells from 13.10% to 41.59%, also in a dose-dependent fashion [1].